Peter Frederick Lang - 18 Mar 2022 Form 4 Insider Report for AERIE PHARMACEUTICALS INC

Role: Chief Financial Officer
Signature: /s/ John LaRocca, Attorney-In-Fact for Peter F. Lang
Issuer symbol: N/A
Transactions as of: 18 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 22 Mar 2022, 20:21:04 UTC
Next filing: 21 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AERI	Common Stock	Award	$0	+46,297		$0.000000	46,297	18 Mar 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AERI	Stock Option (right to buy)	Award	$0	+160,551		$0.000000	160,551	18 Mar 2022	Common Stock	160,551	$8.80	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares of Common Stock were granted under the Aerie Pharmaceuticals, Inc. Amended and Restated Inducement Award Plan (the "Plan") and are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in equal installments on each of the first four anniversaries of March 18, 2022.
F2	This Option was granted under the Plan and is scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, as to 25% of the underlying shares on March 18, 2023 and as to the remaining underlying shares in substantially equal installments on each of the subsequent 36 monthly anniversaries of March 18, 2023.